2022215-59-2
2022215-59-2 structure
- Name: Dostarlimab
- Chemical Name: Dostarlimab
- CAS Number: 2022215-59-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
- Create Date: 2023-01-16 12:36:45
- Modify Date: 2024-09-21 18:59:15
-
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].
| Name | Dostarlimab |
|---|
| Description | Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.5 nM (PD-L2/ PD-1), 1.8 nM (PD-L1/ PD-1)[1] |
| In Vitro | Dostarlimab (10-10000 ng/mL) 以剂量依赖的方式与人和食蟹猴 CD3+ T 细胞上表达的原生 PD-1 受体结合[1]。 Dostarlimab (0-375 nM; 48 h) 在人 CD4+ T 细胞 MLR 实验中增加 IL-2 的产生，EC50 大约为 1 nM，在葡萄球菌肠毒素 B (SEB) 刺激的 PBMC 细胞中增加 IL-2 的产生，EC50 大约为 0.1 nM，增强干扰素 (IFN)-γ 的释放，EC50 大约为 0.5 nM[1]。 |
| In Vivo | Dostarlimab (200 µg/mouse; i.p.; twice weekly for 35 days) 在人源化小鼠模型中显示出抗肿瘤活性[1]。 Animal Model: Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model[1] Dosage: 200 µg/mouse Administration: Intraperitoneal injection; twice weekly for 35 days Result: Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8+ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%). |
| References |
| No Any Chemical & Physical Properties |